CareHub™ generates audited operating revenue through three recurring streams:
hospital/enterprise subscriptions, solo practitioner
subscriptions,
and pharma RWE data licensing. The patient and caregiver app remains
free, the figures
below exclude tokenised ecosystem economics, and the only non-recurring item modeled
here is one
conservative Q4 2026 public-sector pilot booking.
Patient and Caregiver App is
completely free
- 116 languages
- No pop ups
- No ads
- No cross-selling
Provider Pricing Structure
| Tier |
List Price
|
Buyer |
Commercial
Notes |
| Solo Practitioner |
$5 |
Independent physicians, rural GPs, small
clinics |
No EHR integration required. Conservative
floor channel capped at 500
tracked patients per practice. |
| Small Group / Specialty
Clinic |
$8 |
Multi-provider clinics and oncology groups
|
Entry point for coordinated care, reporting,
and caregiver access.
|
| Regional Network |
$12 |
Specialty networks and multi-site provider
groups |
Advanced analytics, custom workflows, and
scaled operational
reporting. |
| Enterprise / IDN |
$15 |
Hospitals, enterprise oncology groups,
national associations |
Headline list price. The long-range model
uses a conservative
$8 blended realized rate across the provider mix.
|
Our
$5-15/tracked-patient/month pricing
remains well below established healthcare SaaS benchmarks:
- CMS RPM Reimbursement (CPT 99453-99458): $19-$61/patient/month
for remote
physiologic monitoring. Medicare pays providers $19.46 (setup) + $50.15/month
(monitoring) +
$41/month (interactive communication).
- Chronic Care Management (CCM): CMS reimburses about
$62/patient/month (CPT
99490), leaving meaningful room for ROI even at our enterprise list rate.
- Cerner HealtheIntent: $5-$12/patient/month for chronic disease
registries,
broadly in line with our mid-market pricing.
- Livongo (pre-Teladoc): $75/member/month for diabetes
monitoring; we offer broader
multi-disease tracking at materially lower cost.
- Omada Health: $130-$350/participant for 16-week programs; our
continuous
longitudinal model is more cost-effective over time.
Sources: CMS 2024
Physician Fee Schedule, AAPC CPT Code Guidelines, Cerner/Oracle Health
enterprise quotes,
Livongo/Teladoc investor materials.
5-Year Revenue Projection (Conservative Core Model)
| Year |
Disease
Modules |
EHR
Patients |
Solo
Patients |
Pharma RWE
|
Total ARR
|
| 2026 |
Cancer, Long COVID, Alzheimer's, Obesity+T2D
|
90-150K* |
~5K |
$1.2M |
$9-15M |
| 2027 |
All 8 diseases (full platform May '27) |
800K |
25K |
$15M |
$80-120M |
| 2028 |
All 8 (scale + IPO) |
2.5M |
75K |
$40M |
$250-350M |
| 2029 |
All 8 (post-IPO expansion) |
5M |
150K |
$80M |
$500-650M |
| 2030 |
All 8 (mature, global) |
7M |
250K |
$150M |
$837M |
Conservative model:
All 8 diseases live by May 2027. IPO target Q4 2027/Q1 2028 at $100M+ ARR.
Enterprise list pricing
runs $8-15/patient/month with a realized blended planning rate of about $8
across the provider mix.
Solo stays at $5/patient/month. 2026 includes modest solo uptake and one
conservative Q4
public-sector pilot worth roughly $0.3M in booked revenue.
Alzheimer's Strategy
- 2027 Alzheimer's revenue: +$12M ARR
- 2028 Alzheimer's revenue: +$43M ARR
- 2029 Alzheimer's revenue: +$96M ARR
- 2030 Alzheimer's revenue: +$216M ARR, taking combined operating
ARR to roughly
$1.05B
Commercial rollout context: Phase 1
focuses on the US,
Canada, Mexico, the UK, and Australia, targeting roughly 10-13 launch
partners,
44,000-70,000 tracked patients, and $9.6-15.5M in
first-year ARR.
Phase 2 then expands through Western Europe, Asia-Pacific, and Latin America before
adding
Scandinavia, Greater China, and the Middle East as the model localizes and scales.
Why the curve steepens: the Alzheimer's
strategy moves
from an estimated 50,000 patients in 2027 to 1.2 million by
2030,
while blended ARPU steps down from $20 to $15 as
the geography mix
broadens. The revenue lift therefore comes from distribution scale and care-network
depth rather than
aggressive pricing.
The
separate Alzheimer's worksheet
also projects a
combined platform outcome of roughly $1.536B by 2031 once Alzheimer's exceeds
$300M ARR.
Revenue Breakdown (2030 Base Case)
- Hospital EHR Subscriptions: $672M (80%) - 7M patients × $8 × 12
- Pharma RWE Data Licensing: $150M (18%) - See detailed breakdown
below
- Solo Practitioner Subscriptions: $15M (2%) - 250K patients × $5
× 12
Total: $837M in
conservative core operating ARR. The solo-practitioner line remains a floor
rather than the main
global growth engine. Upside above $1B comes primarily from stronger enterprise
adoption, major
pharma exclusives, and the Alzheimer's strategy extension.
Key Assumptions
- EHR-tracked patients: Subset of total app users whose providers
have integrated
CareHub
- Pricing discipline: Public list pricing is $5-15 per tracked
patient per month, but
planning uses a conservative $8 blended realized provider rate
- Pharma revenue: Begins in 2027 once patient data volume is
sufficient for RWE
insights
- Public-sector revenue: 2026 includes one modest Q4 pilot booking
only; it is not
modeled as a fourth long-term recurring stream
- Solo practitioner revenue: Conservative bottom-up channel that can
later convert
practices and small groups into larger provider-network or enterprise relationships
Selected Pricing & Operations Sources
- CMS RPM Reimbursement (2024): CPT 99453 ($19.46 setup), 99454 ($50.15/month monitoring), 99457 ($41.17/month interactive) - CMS Physician Fee Schedule 2024
- Chronic Care Management: CPT 99490 ($62/patient/month) - CMS Medicare Physician Fee Schedule
- Cerner HealtheIntent: $5-$12/patient/month for chronic disease registries - Oracle Health enterprise pricing (2024)
- Livongo (pre-Teladoc): $75/member/month diabetes monitoring - Teladoc investor relations and Livongo acquisition materials
- Omada Health: $130-$350 per participant for 16-week programs - enterprise pricing references (2024)
- Patient portal adoption: 62% average at integrated delivery networks - Epic Systems 2024 Annual Report
- RPM outcomes: 20-30% reduction in readmissions - JAMA Network Open 2023
- EHR market share: Epic 36%, Oracle Health/Cerner 25%, Meditech 12% - KLAS Research 2024
- Cultural ambassador model: CDC Healthy Tribes community health worker program outcomes
